Author name: Ananta Kar

Foreign investors grab headlines when they pump billions into Indian markets or trigger panic by pulling capital out. Yet India’s pharmaceutical industry increasingly depends on quieter, steadier hands—domestic institutional investors who don’t flee at the first sign of global turbulence. These homegrown investment powerhouses—mutual funds, insurance companies, pension funds, and banks—have fundamentally reshaped who finances […]

India’s biologics manufacturers just discovered something remarkable: going green actually saves money while winning international contracts simultaneously. Companies like Biocon, Sun Pharma, and Dr. Reddy’s aren’t embracing sustainable biomanufacturing because of environmental activism—they’re doing it because European and North American buyers now demand demonstrable green credentials for procurement contracts. India exported over $7 billion worth

India’s pharmaceutical industry has just placed a massive bet on artificial intelligence, and there’s no turning back now. Companies like Biocon, Dr. Reddy’s, and Cipla aren’t just experimenting with AI anymore—they’re integrating machine learning algorithms directly into drug discovery pipelines, clinical trial designs, and manufacturing processes. This shift from experimental pilots to strategic platforms represents

Ten years ago, India’s bioeconomy barely registered at $10 billion—a modest figure reflecting limited biotechnology commercialization and fragmented industry support. Fast forward to 2024, and that figure has exploded to $165.7 billion, representing one of the fastest biotechnology sector expansions globally. Yet India isn’t stopping there. The government has set an audacious target: building a